TradeShow Talks with Cytosurge

TradeShow Talks with CytosurgeHall B2, Booth 310

Tell us about the company and why you are attending Analytica 2018?

Cytosurge AG manufactures the unique and patented FluidFM technology. We are attending Analytica in order to meet new potential customers, discuss their current and future needs, and to explain what FluidFM is, and how it help researchers to go beyond current technology limitations.

We are equally looking to discuss opportunities with new distribution partners.

What products are you highlighting at analytica 2018?

The ground-breaking FluidFM BOT for Injection and the FluidFM nanosyringe will presented for the first time at Analytica. This system is ideal for researchers looking to inject nanoparticles, proteins, plasmids or CRISPR-Cas complexes into ~10 micron sized cells such iPS or other difficult to transfer cells.

Video of HeLa cells being injected with femtolitres of Lucifer Yellow

What makes this product different from anything else on the market?

Conventional microinjection has its limits: these include limited cell viability, time-consuming experiments and difficulties in injecting into “small” adherent cells.

With FluidFM, compounds can be repeatedly injected into the same cell in a cell-context preserving and non- destructive manner, with more than 95% of the injected cells surviving.

The injected cells can also be cultivated and analyzed, and their evolution captured over time with the integrated time-lapse and video features.

Only 15 minutes are needed to prepare the cells, the well-plates and the nanosyringes before being able to perform the first series of injections.

The FluidFM nanosyringe is capable of successfully injecting adherent cells of around 10 μm in size, such as iPS cells. And repeatedly, into the same living cell.

Download the FluidFM Brochure

Which industries will benefit from this product?

This system is ideal for both academia and industry. The system has been designed with researchers involved in gene engineering, epigenetics, pharmaceutical drug development, toxicology, stem cell and cancer cell research and cell line development in mind.

Cytosurge at Analytica

Cytosurge has a stand with its up and downstream partners at B2.310. Alexander Serre, the Sales and Marketing Director will be glad to show you the ground-breaking FluidFM technology and answer any questions you may have.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cytosurge AG. (2018, May 04). TradeShow Talks with Cytosurge. News-Medical. Retrieved on October 22, 2020 from

  • MLA

    Cytosurge AG. "TradeShow Talks with Cytosurge". News-Medical. 22 October 2020. <>.

  • Chicago

    Cytosurge AG. "TradeShow Talks with Cytosurge". News-Medical. (accessed October 22, 2020).

  • Harvard

    Cytosurge AG. 2018. TradeShow Talks with Cytosurge. News-Medical, viewed 22 October 2020,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.